相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1875
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Bayer and Vanderbilt University Medical Center announced a strategic five-year collaboration agreement to advance innovative therapies from target identification through Investigational New Drug application. - The partnership will initially focus on cardiovascular and kidney diseases, two therapeutic areas with significant unmet medical need, while spanning across all indications currently pursued by Bayer. - The collaboration will leverage VUMC's comprehensive datasets, including the BioVU collection of DNA and plasma, to enable data-driven insights and accelerate drug discovery and development. - The agreement combines Bayer's expertise in drug discovery and translational sciences with VUMC's deep preclinical and clinical knowledge to advance precision medicine approaches.
- Dr. Benjamin P. Brown from Vanderbilt University School of Medicine has developed a novel machine learning framework that addresses the critical generalization problem in AI-driven drug discovery by focusing on molecular interaction physics rather than structural pattern memorization. - The framework demonstrates improved stability and predictability when evaluating binding affinities for novel protein families not present in training data, representing a significant advancement in computational drug design reliability. - Published in PNAS in late 2025, the research introduces rigorous validation protocols that exclude entire protein superfamilies from training to better simulate real-world drug discovery scenarios. - The approach integrates task-specific constraints within neural architectures to learn transferable molecular binding principles, potentially accelerating the identification of therapeutic compounds while reducing computational drug discovery failures.
- Medicare beneficiaries younger than 65 years without supplemental coverage experience higher rates of cost-related medication nonadherence and delayed care compared to those with additional protection. - Enrollment in Medicare Advantage or traditional Medicare with supplemental coverage was associated with better access to care for non-dual-eligible beneficiaries under 65. - Dual-eligible beneficiaries (those with both Medicare and Medicaid) reported minimal differences in financial and access barriers regardless of their Medicare coverage type.
